Candel Therapeutics’ CAN-2409 gains EMA orphan designation

The Phase IIa clinical trial involving CAN-2409 combined with valacyclovir in patients with borderline resectable PDAC, data showed an impressive median overall survival rate. Credit: CDC/Unsplash.